Gene therapy for colorectal cancer

Expert Opinion on Biological Therapy

Volumn 3, Issue 5, 2003, Pages 779-788

  Kerr, D J ^a   Seymour, L W ^a   Maruta, F ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer treatment; Colorectal cancer; Gene therapy; Immunotherapy; Prodrug therapy; Tumour targeting vector

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ALPHA INTERFERON; CARCINOEMBRYONIC ANTIGEN; CC49 ZETA; CISPLATIN; CYCLIN G1; CYCLINE; CYTOSINE DEAMINASE; FLUOROURACIL; GANCICLOVIR; GENE PRODUCT; HLA B7 ANTIGEN; INTERLEUKIN 2; LEUVECTIN; ONCOLYTIC VIRUS; PRODRUG; PROTEIN P53; SCH 58500; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COLORECTAL CANCER; DNA CROSS LINKING; DNA SYNTHESIS; DNA VECTOR; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE THERAPY; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS VECTOR; HUMAN; IMMUNOSTIMULATION; LEUKOPENIA; LIVER TOXICITY; NONHUMAN; REVIEW; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; IMMUNOTHERAPY; PRODRUGS; VIRUSES;

ADENOVIRIDAE; SIMPLEXVIRUS;

EID: 0042170139     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.5.779     Document Type: Review

References (53)

1. FERLAY J, BRAY F, PISANI P, PARKIN DM: Globocan 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No.5. IARCPress, Lyon (2001).
2. EDWARDS BK, HOWE HL, RIES LAG et al.: Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer (2002) 94:2766-2792.
3. CHO KR, VOGELSTEIN B: Genetic alterations in the adenoma-carcinoma sequence. Cancer (1992) 70:1727-1731.
4. FEARON ER, VOGELSTEIN B: A genetic model for colorectal tumorigenesis. Cell (1990) 61:759-767.
5. BOYEL P, LEON ME:. Epidemiology of colorectal cancer. Br. Med. Bull. (2002) 64:1-25.
6. ELMA N, KILLI RM, SEVER A: Colorectal carcinoma: radiological diagnosis and staging. Eur. J. Radiol. (2002) 42:206-223.
7. SCHEELE J, STANG R, ALTENDORF-HOFMANN A, PAUL M: Resection of colorectal liver metastases. World J. Surg. (1995) 19:59-71.
8. MINAGAWA M, MAKUUCHI M, TORZILLI G et al.: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer. Ann. Surg. (2000) 231:487-499.
9. JAMISON RL, DONOHUE JH, NAGORNEY DM, ROSEN CB, HARMSEN WS, ILSTRUP DM: Hepatic resections for metastatic colorectal cancer. Results in cure for some patients. Arch. Surg. (1997) 132:505-511.
10. MIDGLEY R, KERR DJ: Seminar in colorectal cancer. Lancet (1999) 353:391-399.
11. SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. (2000) 343:905-914.
12. DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet (2000) 35:1041-1047.
13. DE GRAMONT A, FIGER A, SEYMOUR M et a.l: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. (2000) 18:2938-2947.
14. PALMER DH, CHEN MJ, KERR DJ: Gene therapy for colorectal cancer. Br. Med. Bull. (2002) 64:201-225.
15. VAN ETTEN B, TEN HAGEN TL, DE VRIES MR, AMBAGTSHEER G, HUET T, EGGERMONT AM: Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody to p21-Ras. Br. J. Cancer (2002) 86:436-442.
16. HARRIS MP, SUTJIPTO S, WILLS KN et al.: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. (1996) 3:121-130. Animal experiment to demonstrate the therapeutic efficacy of gene therapy using wild-type p53 tumour suppressor gene.
17. VENOOK AP, BERGSLAND EK, RING E et al.: Gene therapy of colorectal liver metastasis using recombinant adenovirus encoding wt p53 (SCH58500) via hepatic artery infusion: a Phase I study Proc. Am. Soc. Clin. Oncol. New York, USA (1998) 17:431a. Clinical trial (Phase I) of gene therapy using wild-type p53 tumour suppressor gene for patients with colorectal liver metastasis. No severe adverse events.
18. BURROWS FJ, GORE M, SMILEY WR et al.: Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther. (2002) 9:87-95.
19. HUBER BE, AUSTIN EA, RICHARDS CA, DAVIS ST, GOOD SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA (1994) 91:8302-8306.
20. CRYSTAL RG, HIRSCHOWITZ E, LIEBERMAN M et al.: Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther. (1997) 8:985-1001.
21. HARVEY BG, MARONI J, O'DONOGHUE KA et al.: Safety of local delivery of low- and intermediate-dose adenovirus gene ttansfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther. (2002) 13:15-63.
22. LINK JR CJ, LEVY JP, MCCANN LZ, MOORMAN DW: Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. J. Surg. Oncol. (1997) 64:289-294. Animal experiment to demonstrate the therapeutic efficacy of suicide gene therapy using herpes simplex virus thymidine kinase gene and ganciclovir. Tumour destruction is observed even when gene transfer is effective only to a small portion of the tumour (bystander effect).
23. SUNG MW, YEH HC, THUNG SN et al.: Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a Phase I clinical trial. Mol. Ther. (2001) 4:182-191. Clinical trial (Phase I) of suicide gene therapy using herpes simplex thymidine kinase gene and ganciclovir for patients with colorectal liver metastasis. No severe adverse events.
24. GREEN NK, YOUNGS DJ, NEOPTOLEMOS JP et al.: Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. (1997) 4:229-238. In vitro experiment to demonstrate the therapeutic efficacy of suicide gene therapy using E. coli nitroreductase gene and CB1954.
25. MCNEISH IA, GREEN NK, GILLIGAN MG et al.: Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. ecoli nitroreductase and CB1954. Gene Ther. (1998) 5:1061-1069.
26. CHUNG-FAYE G, PALMER D, ANDERSON D et al: Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A Phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. (2001) 7:2662-2668.
27. FAKHRAI H, SHAWLER DL, GJERSET R et al.: Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther. (1995) 6:591-601.
28. FEARON ER, PARDOLL DM, ITAYA T et al.: Interleukin-2 production by rumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60:397-403.
29. SOBOL RE, SHAWLER DL, CARSON C et al.: Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A Phase I study. Clin. Cancer Res. (1999)5:2359-2365. Clinical trial (Phase I) ofimmunogene therapy using interleukin-2 gene for patients with colorectal cancer. No severe adverse events.
30. SCHMIDT-WOLF IGH, FINKE S, TROJANECK B et al.: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer (1999) 81:1009-1016.
31. GALANIS E, HERSH EM, STOPECK AT et al.: Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience. J. Clin. Oncol. (1999) 17:3313-3323.
32. GILLIGAN MG, KNOX P, WEEDON S et al.: Adenoviral delivery of B7-1 (CD80) increase the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther. (1998) 5:965-974.
33. RUBIN J, GALANIS E, PITOT HC et al.: Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer on an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. (1997) 4:419-425.
34. STOPECK AT, JONES A, HERSH EM et al.: Phase II study of direct intralesional gene transfer of Allovectin-7, an HLA-B7/beta 2-microblobulin DNA-liposome complex, in patients with metastatic melanoma. Clin. Cancer Res. (2001) 7:2285-2291.
35. CHUNG-FAYE GA, KERR DJ, YOUNG LS, SEARLE PF: Gene therapy strategies for colon cancer. Mol. Med. Today (2000) 6:82-87.
36. KANTOR J, IRVINE K, ABRAMS S, KAUFMAN H, DIPOETRO J, SCHLOM J: Anti-tumor activity and immune responses induced by a recombinant CEA-vaccinia virus vaccine. J. Natl. Cancer Inst. (1992) 84:1084-1091.
37. BRAMSON JL, WAN YH: The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opin. Biol. Ther. (2002) 2:75-85.
38. CONRY RM, ALLEN KO, LEE S, MOORE SE, SHAW DR, LOBUGLIO AF: Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res. (2000) 6:3441. Clinical trial (Phase I) of immunogene therapy using recombinant vaccinia viruses encoding CEA gene for patients with CEA-positive adenocarcinoma. No severe adverse events.
39. MARSHALL JL, HAWKINS MJ, TSANG KY et al.: Phase I study in cancer patients of replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. (1999) 17:332-338.
40. KIRN D.: Oncolytic virotherapy for cancer with the adenovirus dl1520 (ONYX-015): results of Phase I and H trials. Expert Opin. Biol. Ther. (2001) 1:525-538. Clinical trial (Phase I and II) of gene therapy using genetically modified oncolytic virus (ONYX-015) for cancer patients. The virus was well-tolerated and local tumour regression rate was up to 14%.
41. HABIB NA, SARRAF CE, MITRY RR et al.: E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther. (2001) 12:219-226.
42. REID T, GALANIS E, ABBRUZZESE J et al.: Hepatic arterial infusion of a replication-selective oncolydc adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. (2002) 62:6070-6079.
43. BENNETT JJ, DELMAN KA, BURT BM et al.: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. (2002) 9:935-945.
44. VARGHESE S, RABKIN SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. (2002) 9:967-978.
45. HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. (2000) 49:504-514.
46. CHEN SH, KOSAI K, XU B et al.: Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. (1996) 56:3758-3762.
47. OGAWA N, FUJIWARA T, KAGAWA S et al.: Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J. Cancer (1997) 73:367-370.
48. MARUTA F, PARKER AL, FISHER KD et al.: Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther. (2002) 9:543-552. Use of phage display library (biopanning procedure) for tumour targeting in cancer gene therapy.
49. HOLLON T: Researchers and regulators reflect on first gene therapy death. Nat. Med. (2000) 6:6. Report of the first death related to adenoviral vector in gene therapy.
50. KAISER J: Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science (2003) 299:495.
51. RICHARDS CA, AUSTIN EA, HUBER BE: Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. (1995) 6:881-893.
52. FISHER KD, STALLWOOD Y, GREEN NK, ULBRICH K, MAUTNER V, SEYMOUR LW: Polymercoated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. (2001) 8:341-348.
53. ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 279:377-380.